Oncotarget

Vol 10, No 37

May 28, 2019

View Archive »

Order a Reprint

About The Cover

The cover for issue 37 of Oncotarget features Figure 7, "Flow diagram illustrating doxorubicin and 5FU chemoresistance in breast cancer tumors," by Ullah, et al.

Table of Contents

Editorial

Organ preservation for T2-T3 rectal cancer: opportunistic or planned strategy

Organ preservation for T2-T3 rectal cancer: opportunistic or planned strategy

https://doi.org/10.18632/oncotarget.26916

Jéan-Pierre Gérard, Nicolas Barbet,  and Karen Benezery
3431-3432
PDF  |  Order a Reprint

circPSMC3: ceRNA and tumor suppressor

circPSMC3: ceRNA and tumor suppressor

https://doi.org/10.18632/oncotarget.26953

Chen Lu, Dawei Rong,  and Weiwei Tang
3433-3434
PDF  |  Order a Reprint

Priority Research Papers

Mesenchymal stem cells confer chemoresistance in breast cancer via a CD9 dependent mechanism

Mesenchymal stem cells confer chemoresistance in breast cancer via a CD9 dependent mechanism

https://doi.org/10.18632/oncotarget.26952

Mujib Ullah, Asma Akbar, Nathan Norton Ng, Waldo Concepcion,  and Avnesh S. Thakor
3435-3450
Abstract  |  PDF  |  HTML  |  Order a Reprint

Research Papers: Immunology

Endotoxin tolerance modulates TREG and TH17 lymphocytes protecting septic mice

Endotoxin tolerance modulates TREG and TH17 lymphocytes protecting septic mice

https://doi.org/10.18632/oncotarget.26919

Mariana M.C. Andrade, Suely S.K. Ariga, Denise F. Barbeiro, Hermes V. Barbeiro, Rosangela N. Pimentel, Ricardo C. Petroni,  and Francisco G. Soriano
3451-3461
Abstract  |  PDF  |  HTML  |  Order a Reprint

Research Papers

The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells

The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells

https://doi.org/10.18632/oncotarget.26877

Kathryn Clarke, Christine Young, Fabio Liberante, Mary-Frances McMullin, Alexander Thompson,  and Ken Mills
3462-3471
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates heptotoxicity via phase I and II drug metabolizing enzymes

Frankincense essential oil suppresses melanoma cancer through down regulation of Bcl-2/Bax cascade signaling and ameliorates heptotoxicity via phase I and II drug metabolizing enzymes

https://doi.org/10.18632/oncotarget.26930

Faruck L. Hakkim, Hamid A. Bakshi, Shabia Khan, Mohamad Nasef, Rabia Farzand, Smitha Sam, Luay Rashan, Mohammed S. Al-Baloshi, Sidgi Syed Anwar Abdo Hasson, Ali Al Jabri, Paul A. McCarron,  and Murtaza M. Tambuwala
3472-3490
Abstract  |  PDF  |  HTML  |  Order a Reprint

IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways

IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways

https://doi.org/10.18632/oncotarget.26834

István Gyurján, Sandra Rosskopf, Johana A. Luna Coronell, Daniela Muhr, Christian Singer,  and Andreas Weinhäusel
3491-3505
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas

Comparative genomic analysis of driver mutations in matched primary and recurrent meningiomas

https://doi.org/10.18632/oncotarget.26941

Joshua Loewenstern, John Rutland, Corey Gill, Hanane Arib, Margaret Pain, Melissa Umphlett, Yayoi Kinoshita, Russell McBride, Michael Donovan, Robert Sebra, Joshua Bederson, Mary Fowkes,  and Raj Shrivastava
3506-3517
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators

Synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators

https://doi.org/10.18632/oncotarget.26943

Gang Cheng, Jacek Zielonka, Micael Hardy, Olivier Ouari, Christopher R. Chitambar, Michael B. Dwinell,  and Balaraman Kalyanaraman
3518-3532
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options

Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options

https://doi.org/10.18632/oncotarget.26947

Marilyne Labrie, Tae-Beom Kim, Zhenlin Ju, Sanghoon Lee, Wei Zhao, Yong Fang, Yiling Lu, Ken Chen, Pedro Ramirez, Michael Frumovitz, Larissa Meyer, Nicole D. Fleming, Anil K. Sood, Robert L. Coleman, Gordon B. Mills,  and Shannon N. Westin
3533-3546
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile

In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile

https://doi.org/10.18632/oncotarget.26949

Shuhei Suzuki, Masahiro Yamamoto, Keita Togashi, Tomomi Sanomachi, Asuka Sugai, Shizuka Seino, Takashi Yoshioka, Chifumi Kitanaka,  and Masashi Okada
3547-3558
Abstract  |  PDF  |  HTML  |  Order a Reprint

Interleukin 1 is a key driver of inflammatory bowel disease-demonstration in a murine IL-1Ra knockout model

Interleukin 1 is a key driver of inflammatory bowel disease-demonstration in a murine IL-1Ra knockout model

https://doi.org/10.18632/oncotarget.26894

Rasha H. Dosh, Nicola Jordan-Mahy, Christopher Sammon,  and Christine Le Maitre
3559-3575
Abstract  |  PDF  |  HTML  |  Supplementary Information  |  Order a Reprint

Corrections

Correction: The role of substance P in epilepsy and seizure disorders

Correction: The role of substance P in epilepsy and seizure disorders

https://doi.org/10.18632/oncotarget.26991

Xue Feng Wang, Tong Tong Ge, Jie Fan, Wei Yang, Li Bingjin,  and Ran Ji Cui
3576-3576
Correction  |  PDF

Correction: Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress

Correction: Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress

https://doi.org/10.18632/oncotarget.26997

Yu-Chin Lin, Meng-Hsuan Wu, Tzu-Tang Wei, Yun-Chieh Lin, Wen-Chih Huang, Liang-Yu Huang, Yi-Ting Lin,  and Ching-Chow Chen
3577-3578
Correction  |  PDF


Copyright © 2019 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC